STOCK TITAN
  1. Home
  2. News
  3. CSTL

Castle Biosciences, Inc. - CSTL STOCK NEWS

Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.

Castle Biosciences, Inc. (symbol: CSTL) is a pioneering company specializing in diagnostic tests for a variety of cancers. Founded in 2008, Castle Biosciences has dedicated itself to advancing cancer care through objective and accurate testing. The company's primary mission is to provide physicians and patients with personalized, clinically actionable genomic information to facilitate more precise treatment decisions.

Castle Biosciences offers a range of diagnostic tests that assist doctors in the treatment of various cancers. Their current product portfolio includes tests for cutaneous melanoma, uveal melanoma, esophageal adenocarcinoma, mesothelioma, and glioma. Notably, their products include DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME, all designed to provide vital information that can influence the course of cancer treatment.

The company is not just limited to its existing portfolio; it actively engages in research programs aimed at developing diagnostic tests for other under-served cancers, such as rectal cancer and soft tissue sarcoma. These initiatives underscore Castle Biosciences' commitment to addressing gaps in cancer diagnostics and improving patient outcomes.

Castle Biosciences collaborates closely with leading members of the oncology community to ensure that their tests are both innovative and clinically relevant. This collaboration spans the discovery, development, and practical utilization of their diagnostic tests, reinforcing their standing as a crucial player in the field of cancer diagnostics.

The company is currently in a robust financial condition, reflecting its successful commercialization efforts and consistent revenue growth. Recent achievements include expanding their test portfolio and forging strategic partnerships aimed at broadening their market reach and enhancing their technological capabilities.

For the latest updates and detailed information on Castle Biosciences, Inc. and its products, please visit their official website at www.castlebiosciences.com.

News

Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results

Rhea-AI Summary
Castle Biosciences, Inc. (Nasdaq: CSTL) expects to deliver total revenue of over $210 million in 2023, representing at least 53% growth over 2022. The company also anticipates cash, cash equivalents, and marketable investment securities to be approximately $243 million by the end of 2023. The preliminary, unaudited results for the fourth quarter and full year ended Dec. 31, 2023, show significant growth in test reports delivered, indicating a successful year for Castle Biosciences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.14%
Tags
earnings
-
News

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Castle Biosciences, Inc. (Nasdaq: CSTL) granted restricted stock units to 52 employees covering 170,913 shares of common stock as an inducement material to their entering into employment. The RSUs will vest over four years, with 25% of the shares vesting on the first anniversary of the applicable vesting commencement date, and the balance vesting annually thereafter in three equal installments, subject to the employee’s continued service through each applicable vesting date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.85%
Tags
none
-
News

Study Finds Nurse Practitioners and Physician Assistants Would Alter Patient Care Decisions Based on DecisionDx®-Melanoma Test Results

Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) published a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that revealed 82.4% of NPs/PAs using DecisionDx-Melanoma in clinical practice would change patient treatment plans based on high-risk test results in thin melanoma tumors. Similarly, 81.3% would alter treatment plans for Stage 1 tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
none
News

Castle Biosciences Announces Multiple Data Presentations at the 2023 American Society for Dermatologic Surgery Annual Meeting

Rhea-AI Summary
Castle Biosciences, Inc. (Nasdaq: CSTL) presented robust data at the 2023 ASDS Annual Meeting, reinforcing the clinical validity and utility of its skin cancer test portfolio. The data highlighted the DecisionDx-Melanoma and DecisionDx-SCC tests, demonstrating their ability to predict tumor recurrence in stage I cutaneous melanoma and identify patients at less than 5% risk of sentinel lymph node biopsy metastasis. The DecisionDx-SCC test was also shown to reduce healthcare costs and improve metastatic risk assessment for cutaneous squamous cell carcinoma patients. MyPath Melanoma testing was presented as a valuable tool in the diagnostic work-up of ambiguous melanocytic neoplasms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.01%
Tags
none
-
News

Castle Biosciences Ranked Among the Top Workplaces in Houston by the Houston Chronicle for the Third Consecutive Year

Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) Earns National Recognition and Three Top Workplaces Culture Excellence Awards
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.14%
Tags
none
-
News

Real-World Evidence Confirms IDgenetix®-Guided Medication Management Significantly Improves Response and Remission Rates in Patients with Major Depressive Disorder

Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) announces data from a study demonstrating the consistent impact of IDgenetix on medication response and remission rates in patients with major depressive disorder (MDD). Results show that patients whose medication management was guided by IDgenetix were 2.65 times more likely to achieve remission of depressive symptoms compared to patients whose medication management was not guided by the test. The study compared clinical outcome results from a multi-center randomized controlled trial (RCT) to real-world evidence (RWE) from a single-center, non-randomized, open-label study. Response and remission rates for patients with moderate to severe MDD were analyzed, showing strong alignment between both studies. The impact of drug-drug interactions (DDI) and lifestyle factors on the test results was also highlighted, indicating the unique aspects of IDgenetix.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.62%
Tags
none
News

Castle Biosciences to Present at Upcoming Investor Conferences

Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) to Present Company Overview at Investor Conferences in November 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.22%
Tags
conferences
-
News

Castle Announces Early Exploratory Study Data for Potential Development of a Complementary Test to Accompany DecisionDx®-UM That Could Aid in the Early Detection of Uveal Melanomas

Rhea-AI Summary
Castle Biosciences, Inc. announced new discovery data from a study exploring the potential for developing a complementary test to evaluate small, suspicious lesions of uncertain malignant potential in patients' eyes. The data will be presented at the 2023 American Academy of Ophthalmology Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.99%
Tags
none
-
News

Early Discovery Data Shows Ability of Castle Biosciences’ Pipeline Program to Distinguish Between Responders and Non-Responders to an Atopic Dermatitis Therapy

Rhea-AI Summary
Castle Biosciences, Inc. plans to launch a genomic test by the end of 2025 that can guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis, and related conditions. New data shows the test's ability to distinguish between responders and non-responders to an atopic dermatitis therapy, as well as differentiate between atopic dermatitis, psoriasis, and mycosis fungoides skin lesions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.99%
Tags
none
News

Castle Biosciences Reports Third Quarter 2023 Results

Rhea-AI Summary
Castle Biosciences reports exceptional Q3 2023 results with a 66% increase in revenue to $61.5 million and a 52% increase in total test reports. They raise their full-year 2023 revenue guidance to at least $200 million from $180 million. Gross margin for Q3 was 78% and adjusted gross margin was 81%. Net cash provided by operations was $5.0 million, and adjusted EBITDA was $6.6 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.99%
Tags
earnings

FAQ

What is the current stock price of Castle Biosciences (CSTL)?

The current stock price of Castle Biosciences (CSTL) is $25.46 as of January 14, 2025.

What is the market cap of Castle Biosciences (CSTL)?

The market cap of Castle Biosciences (CSTL) is approximately 697.1M.

What does Castle Biosciences specialize in?

Castle Biosciences specializes in diagnostic tests for various cancers, providing genomic information to aid in treatment decisions.

When was Castle Biosciences founded?

Castle Biosciences was founded in 2008.

What types of cancer does Castle Biosciences have tests for?

Castle Biosciences has tests for cutaneous melanoma, uveal melanoma, esophageal adenocarcinoma, mesothelioma, and glioma.

What are some of Castle Biosciences' notable products?

Notable products include DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME.

Is Castle Biosciences involved in research for new diagnostic tests?

Yes, they have active research programs in rectal cancer and soft tissue sarcoma, among others.

Where can I find more information about Castle Biosciences and its products?

You can visit their official website at www.castlebiosciences.com for more detailed information.

What is the primary mission of Castle Biosciences?

The primary mission is to provide personalized, clinically actionable genomic information to make more accurate treatment decisions.

Does Castle Biosciences collaborate with other entities?

Yes, they work closely with outstanding members of the oncology community throughout the discovery, development, and utilization of their tests.

What is Castle Biosciences' financial condition?

The company is in a robust financial condition, reflecting successful commercialization efforts and consistent revenue growth.

How does Castle Biosciences contribute to cancer care?

By providing objective and accurate diagnostic tests, Castle Biosciences helps advance cancer care and improve patient outcomes.
Stock CSTL logo
Castle Biosciences, Inc.

Nasdaq:CSTL

CSTL Rankings

#2825 Ranked by Market Cap
N/A Ranked by Dividends

CSTL Stock Data

697.10M
27.07M
3.38%
94.29%
6%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
FRIENDSWOOD